Biosurfit Lands CE Mark For New Three-In-One POC HbA1c Test
Executive Summary
IVD-maker biosurfit is seeking more distribution partners to roll out its new three-in-one POC HbA1c blood test across Europe. The IVD company secured CE-marking for the test to assist doctors diagnose and monitor diabetes.
You may also be interested in...
OUS Approvals Analysis: November Product Go-Aheads Headlined by LimFlow, Abbott, Creavo
The number of medical device approvals reported outside the US rebounded in November after a very slow October. There were 14 CE marks, three approvals in Japan, and three in Canada last month, covering nine different product categories.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.